AZN.L - AstraZeneca PLC
| Previous close | 5,175.00 |
| Open | 5,182.00 |
| Bid | 5,100.00 x 6100 |
| Ask | 5,200.00 x 13000 |
| Day's range | 5,156.47 - 5,251.50 |
| 52-week range | 3,996.00 - 5,520.00 |
| Volume | 1,809,138 |
| Avg. volume | 2,548,568 |
| Market cap | 65.35B |
| Beta | 0.63 |
| PE ratio (TTM) | 16.93 |
| EPS (TTM) | 304.9 |
| Earnings date | 9 Nov 2017 |
| Forward Dividend & Yield | 2.79 (4.51%) |
| Ex-dividend date | 2017-08-10 |
| 1y target est | 66.80 |
- Fool.co.uk•4 hours ago
Why I see more upside ahead for AstraZeneca plc
I believe that AstraZeneca plc's (LON: AZN) growth is only just getting started and there's still plenty of potential for investors.
- Zacks•15 hours ago
Cancer Treatment Update: Second Gene Therapy Receives Approval
The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.
- Zacks•2 days ago
AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review
AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.
- Reuters•2 days ago
China biotech's 'coming out party' masks long road ahead
LONDON/SHANGHAI (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares in firms such as Chi-Med (HCM.L), Beigene (BGNE.O) and Zai Lab (ZLAB.O) have soared on international markets this year, fuelled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (AZN.L).
- Reuters - UK Focus•2 days ago
China biotech's 'coming out party' masks long road ahead
LONDON/SHANGHAI, Oct (Shenzhen: 000069.SZ - news) 19 (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares (Berlin: DI6.BE - news) in firms such as Chi-Med, Beigene and Zai Lab have soared on international markets this year, fuelled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (NYSE: AZN - news) .
- Market Realist•3 days ago
What AstraZeneca’s 3Q17 Performance Tells Us
AZN stock rose ~0.9% in 3Q17 and has risen ~26.9% YTD (year-to-date) as of October 16.
- Reuters - UK Focus•3 days ago
Astra and Merck win speedy review for Lynparza in breast cancer
U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during ...
- Reuters - UK Focus•4 days ago
Chi-Med, AstraZeneca lung cancer drug shrinks resistant tumours
LONDON, Oct (Shenzhen: 000069.SZ - news) 17 (Reuters) - An experimental cancer drug discovered by Hutchison China MediTech has demonstrated promising activity in shrinking tumours in lung cancer patients whose disease had worsened following treatment with approved medicines. The treatment, which Hutchison China MediTech or "Chi-Med" is developing with AstraZeneca (NYSE: AZN - news) , is one of a new wave of innovative medicines coming out of Chinese research labs as the country flexes its muscles in drug discovery. Results from small-scale studies presented on Tuesday at a medical meeting in Japan showed that adding savolitinib to either AstraZeneca's Tagrisso or Iressa improved responses.
- Business Wire•4 days ago
Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification
LONDON--(BUSINESSWIRE)-- – Data for savolitinib in combination with Tagrisso ® or Iressa ® presented at World Conference on Lung Cancer – – New data give insights into disease progression and potential ...
- Zacks•5 days ago
Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
Foreign markets remain undeterred by discouraging events, notching up weekly gains.
Reuters•5 days agoPharma and medtech industries prepare for hard Brexit
Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small service businesses are already relocating to stay inside the bloc. MeddiQuest, an eight-person consultancy specialising in medical technology regulations, is in the process of moving from outside Cambridge to Ireland. "A significant part of our business is being an authorised EU representative," Chief Executive Neil Armstrong told Reuters.
- Reuters - UK Focus•5 days ago
Pharma and medtech industries prepare for hard Brexit
LONDON, Oct (Shenzhen: 000069.SZ - news) 16 (Reuters) - Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small service businesses are already relocating to stay inside the bloc. MeddiQuest, an eight-person consultancy specialising in medical technology regulations, is in the process of moving from outside Cambridge to Ireland (Other OTC: IRLD - news) .
- Bloomberg•5 days ago
Drug Companies Fear Brexit Will Hit Medicine Trade
Time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.
- Zacks•8 days ago
Cancer Space Update: Lung & Breast Cancer Studies in Focus
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
- Reuters - UK Focus•11 days ago
Pfizer weighs $15 bln sale of consumer healthcare business
Oct (Shenzhen: 000069.SZ - news) 10 (Reuters) - Pfizer (NYSE: PFE - news) said on Tuesday it was considering the sale or spin-off of its consumer healthcare business, shaking up the industry and potentially putting a headache pill to lip balm operation worth some $15 billion up for grabs. The move comes as Germany's Merck KGaA (LSE: 0O14.L - news) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years.
Reuters•11 days agoPfizer weighs $15 bln sale of consumer healthcare business
The move comes as Germany's Merck KGaA (MRCG.DE) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years. Pfizer's consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.
- Zacks•12 days ago
AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.
- Reuters•15 days ago
FTSE at two-month peak as sterling falters
British shares edged higher on Friday and held to their highest level in two months as political uncertainties linked to Theresa's May's premiership pushed the pound lower, giving a boost to dollar-earning groups such as pharma stocks. The FTSE 100 index (.FTSE) closed 0.2 percent up at 7,522.87 points, with Britain's pound on track for its worst week in a year as the Prime Minister hit back at a plot to topple her, saying she would provide "calm leadership" to the country. "The talk of a leadership plot against the Prime Minister is eroding the pound's value and propping up the FTSE 100," CMC Markets analyst David Madden wrote in a note to clients.
- Reuters - UK Focus•15 days ago
Britain's FTSE at two-month peak as sterling falters
British shares edged higher on Friday and held to their highest level in two months as political uncertainties linked to Theresa's May's premiership pushed the pound lower, giving a boost to dollar-earning ...
- Reuters - UK Focus•15 days ago
Britain's FTSE scales 2-month peak
The UK's top share index advanced on Friday, holding at its highest level in two months as a weaker pound boosted dollar-earning constituents such as consumer firms and pharma stocks. A dip in the pound ...
Reuters•16 days agoDrug industry gives up legal battle over new UK cost curbs
Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.
- Reuters - UK Focus•16 days ago
Drug industry gives up legal battle over new UK cost curbs
LONDON, Oct (Shenzhen: 000069.SZ - news) 5 (Reuters) - Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.
- Reuters - UK Focus•17 days ago
Drug industry fails to win judicial review of new UK cost curbs
LONDON, Oct (Shenzhen: 000069.SZ - news) 4 (Reuters) - Britain's pharmaceuticals industry failed to secure a judicial review of new cost curbs, which mean drugs costing NHS England more than 20 million pounds ($26 mln) annually no longer get automatic funding. The Association of the British Pharmaceutical Industry (ABPI) had sought to challenge the additional hurdle to drug uptake that was implemented by the National Institute for Health and Care Excellence (NICE (Other OTC: NCSYF - news) ) earlier this year. On Wednesday it said it was disappointed the judicial review application had been turned down.
Reuters•19 days agoTell us how Brexit will work, British companies demand
British companies including pharmaceuticals giant AstraZeneca urged the government on Monday to agree a three-year Brexit transitional deal to ease the uncertainty hampering investment decisions and the economy. Britain's biggest companies have become increasingly alarmed by the slow progress of Brexit negotiations and the prospect the country could crash out of the world's biggest trading bloc without a deal in 2019. Prime Minister Theresa May vowed in a speech last month to seek a two-year transition deal to help reduce the disruption, but her efforts were overshadowed by a challenge from Foreign Secretary Boris Johnson who has set out his own terms for Britain leaving the European Union.
- Reuters - UK Focus•19 days ago
Tell us how Brexit will work, British companies demand
MANCHESTER, England, Oct (Shenzhen: 000069.SZ - news) 2 (Reuters) - British companies including pharmaceuticals giant AstraZeneca (NYSE: AZN - news) urged the government on Monday to agree a three-year Brexit transitional deal to ease the uncertainty hampering investment decisions and the economy. Britain's biggest companies have become increasingly alarmed by the slow progress of Brexit negotiations and the prospect the country could crash out of the world's biggest trading bloc without a deal in 2019. Prime Minister Theresa May vowed in a speech last month to seek a two-year transition deal to help reduce the disruption, but her efforts were overshadowed by a challenge from Foreign Secretary Boris Johnson who has set out his own terms for Britain leaving the European Union.
